TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
Open accessPublished version of a preprint
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy remains the major cause of treatment failure in patients with colorectal cancer (CRC). Here, we identified TRIM25 as an epigenetic regulator of oxaliplatin (OXA) resistance in CRC. The level of TRIM25 in OXA-resistant patients who experienced recurrence during the follow-up period was significantly higher than in those who had no recurrence. Patients with high expression of TRIM25 had a significantly higher recurrence rate and worse disease-free survival than those with low TRIM25 expression. Downregulation of TRIM25 dramatically inhibited, while overexpression of TRIM25 increased, CRC cell survival after OXA treatment. In addition, TRIM25 promoted the stem cell properties of CRC cells both in vitro and in vivo. Importantly, we demonstrated that TRIM25 inhibited the binding of E3 ubiquitin ligase TRAF6 to EZH2, thus stabilizing and upregulating EZH2, and promoting OXA resistance. Our study contributes to a better understanding of OXA resistance and indicates that inhibitors against TRIM25 might be an excellent strategy for CRC management in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Targeting EZH2 may also be an effective strategy to overcome oxaliplatin resistance, since EZH2 was shown to promote oxaliplatin resistance in CRC cells, while EZH2 inhibitor suppressed tumor growth and sensitized CRC cells to oxaliplatin [172,173].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [172]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., Lu, L., Irvin, D., Black, K. L., & Yu, J. S. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-67 · Cited by 1,790
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity
Gack, M. U., Shin, Y. C., Joo, C.-H., Urano, T., Liang, C., Sun, L., Takeuchi, O., Akira, S., Chen, Z., Inoue, S., et al. (2007) · Nature · doi:10.1038/nature05732 · Cited by 1,695
Kim, E., Kim, M., Woo, D.-H., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.008 · Cited by 806
Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3
Cha, T.-L., Zhou, B. P., Xia, W., Wu, Y., Yang, C.-C., Chen, C.-T., Ping, B., Otte, A. P., & Hung, M.-C. (2005) · Science · doi:10.1126/science.1118947 · Cited by 548
Self-renewal as a therapeutic target in human colorectal cancer
Kreso, A., van Galen, P., Pedley, N. M., Lima-Fernandes, E., Frelin, C., Davis, T., Cao, L., Baiazitov, R., Du, W., Sydorenko, N., et al. (2014) · Nature Medicine · doi:10.1038/nm.3418 · Cited by 500
Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
Lee, S. T., Li, Z., Wu, Z., Aau, M., Guan, P., Karuturi, R. K. M., Liou, Y. C., & Yu, Q. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.011 · Cited by 399
Cited by
Li, J., Liu, J., Zhou, Z., Wu, R., Chen, X., Yu, C., Stockwell, B., Kroemer, G., Kang, R., & Tang, D. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3049 · Cited by 275
Huang, Y., Yang, W., Yang, L., Wang, T., Li, C., Yu, J., Zhang, P., Yin, Y., Li, R., & Tao, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-41490-x · Cited by 85
“Chemotherapy is an important means of postoperative treatment for patients with advanced CRC, which can effectively prolong the survival time of patients, but the drug resistance of tumor cells is the main reason for the failure of chemotherapy 29 .”
BackgroundDrug and apoptosis resistance in cancer stem cells (CSCs): A puzzle with many pieces
Safa, A. R. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.20 · Cited by 84
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Targeting EZH2 may also be an effective strategy to overcome oxaliplatin resistance, since EZH2 was shown to promote oxaliplatin resistance in CRC cells, while EZH2 inhibitor suppressed tumor growth and sensitized CRC cells to oxaliplatin [172,173].”
Guo, Y., Cheng, R., Wang, Y., Gonzalez, M. E., Zhang, H., Liu, Y., Kleer, C. G., & Xue, L. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.104972 · Cited by 66
“43 – 47 In these studies, TRAF6 was fi rst reported as the direct E3 ligase of EZH2 in 2017.”
Background
Metadata
- Authors
- Zhou, S., Peng, J., Xiao, L., Zhou, C., Fang, Y., Ou, Q., Qin, J., Liu, M., Pan, Z., & Hou, Z.
- Affiliations
- Sun Yat-sen University Cancer Center (CN)
- Tongji Hospital (CN)
- Corresponding author
- Pan, Zhizhong
- Hou, Zhenlin
- ORCID
- Venue
- Cell Death & Disease
- Published
- 2021-05-08
- Volume
- 12
- Issue
- 5
- Pages
- 463-463
- ISSN
- 2041-4889 (ISSN-L)
- PMC
- PMC8106682
- OpenAlex
- W3110336364
- Cited by
- 66
- References
- 47
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 14 · 2023: 15 · 2022: 8 · 2021: 2
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death and Disease (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Natural Science Foundation of Guangdong Province (2019A1515110144)
- China Postdoctoral Science Foundation (2019M663289)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- TRIM25, oxaliplatin resistance, colorectal cancer, TRAF6, E3 ubiquitin ligase, epigenetic regulation, chemoresistance, tumor recurrence, cancer stemness, disease-free survival
- MeSH terms
- Tripartite Motif Proteins, Enhancer of Zeste Homolog 2 Protein, Oxaliplatin, Antineoplastic Agents, Humans, Transcription Factors, Colorectal Neoplasms, Drug Resistance, Neoplasm, Ubiquitin-Protein Ligases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability. https://app.cochat.ai/papers/10.1038/s41419-021-03734-4
- The paper
- Zhou, S., Peng, J., Xiao, L., Zhou, C., Fang, Y., Ou, Q., Qin, J., Liu, M., Pan, Z., & Hou, Z. (2021). TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability. Cell Death & Disease. https://doi.org/10.1038/s41419-021-03734-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.